Alector (ALEC) Set to Announce Earnings on Thursday

Alector (NASDAQ:ALEC) is projected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $2.19 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Alector (NASDAQ:ALEC) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. The firm had revenue of $3.32 million for the quarter, compared to analyst estimates of $1.71 million. Alector had a negative return on equity of 531.03% and a negative net margin of 850.13%. On average, analysts expect Alector to post ($0.47) EPS for the current fiscal year and ($0.78) EPS for the next fiscal year.

Alector Price Performance

Shares of NASDAQ ALEC opened at $2.05 on Wednesday. The company has a quick ratio of 5.26, a current ratio of 5.26 and a debt-to-equity ratio of 0.80. The business has a fifty day moving average price of $2.07 and a two-hundred day moving average price of $2.03. Alector has a fifty-two week low of $1.09 and a fifty-two week high of $2.76.

Insiders Place Their Bets

In related news, CEO Arnon Rosenthal sold 72,606 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $2.66, for a total value of $193,131.96. Following the sale, the chief executive officer directly owned 2,294,600 shares of the company’s stock, valued at $6,103,636. This trade represents a 3.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Neil Berkley sold 29,251 shares of Alector stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $2.66, for a total value of $77,807.66. Following the completion of the transaction, the chief financial officer owned 350,649 shares in the company, valued at approximately $932,726.34. This represents a 7.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 111,303 shares of company stock valued at $295,633 in the last three months. 8.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ALEC. Weiss Ratings raised Alector from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. UBS Group restated a “neutral” rating and issued a $1.50 price target on shares of Alector in a research report on Tuesday, October 6th. Morgan Stanley boosted their price target on Alector from $2.00 to $3.00 and gave the company an “underweight” rating in a research note on Tuesday, October 6th. Finally, HC Wainwright upped their price objective on shares of Alector from $5.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $4.62.

Alector Company Profile

Alector, Inc (NASDAQ: ALEC) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s research platform, known as immuno-neurology, is designed to use the body’s immune system to protect or restore the brain’s ability to maintain healthy neural connections.

Alector’s investigational pipeline has included antibody-based treatments for conditions such as frontotemporal dementia and Alzheimer’s disease. Its programs have targeted biological pathways associated with neurodegeneration, including progranulin and TREM2.